Hypersensitivity Reactions Explained: 6 High-Yield Facts for MRCEM Primary Pathology Revision

MRCEM Primary pathology revision is a core part of UK Emergency Medicine practice. Hypersensitivity reactions occupy a deceptively broad slice of the MRCEM Primary syllabus. At one end of the clinical spectrum sits urticaria; at the other, refractory anaphylaxis with cardiovascular collapse. Understanding the immunological framework that underpins all four mechanistic types is not merely an academic exercise — it directly informs why adrenaline reverses Type I anaphylaxis, why plasmapheresis has a role in Type III disease, and why topical steroids rather than antihistamines are the mainstay for Type IV contact dermatitis. For candidates preparing for the MRCEM Primary exam, the Gell and Coombs classification is a perennial source of single best answer (SBA) questions, and a precise grasp of the cellular and humoral pathways separates a confident pass from a near miss.

Definition, Epidemiology, and Clinical Relevance in Emergency Medicine

Hypersensitivity reactions are pathological, exaggerated immune responses to antigens that result in tissue damage rather than protective immunity. They differ from physiological inflammation in that the immune response itself becomes the injurious agent. The Gell and Coombs classification, first described in 1963 and refined over subsequent decades, divides these reactions into four types based on the effector mechanism responsible for tissue injury.

In the UK Emergency Department, hypersensitivity reactions are encountered daily. Resuscitation Council UK estimates that anaphylaxis — the most severe manifestation of Type I hypersensitivity — affects approximately 1 in 1,333 of the UK population at some point during their lifetime, with food, drugs, and insect venom representing the most common triggers in adults. Drug-induced haemolytic anaemia (Type II), serum sickness secondary to antivenom or biological agents (Type III), and occupational contact dermatitis (Type IV) are all presentations a UK registrar will encounter across acute medical and ED settings. The MRCEM Primary syllabus explicitly maps to the RCEM curriculum domain of basic sciences, which includes immunopathology, making this a predictable and heavily tested area in both the MRCEM SBA and FRCEM SBA examinations.

Pathophysiology: The Gell and Coombs Classification in Detail

A structured understanding of each type — mediator, mechanism, onset, and prototypical example — is the foundation of reliable exam performance and sound clinical reasoning.

Type I — Anaphylactic (IgE-Mediated)

On first exposure to an antigen (the sensitisation phase), antigen-presenting cells activate B lymphocytes via Th2 helper cells, driving class switching to produce antigen-specific IgE. This IgE binds high-affinity Fc-epsilon-RI receptors on the surface of mast cells in tissues and circulating basophils. On re-exposure, antigen cross-links adjacent IgE-receptor complexes, triggering intracellular signalling cascades — phospholipase C activation and a rapid rise in cytosolic calcium — culminating in degranulation within seconds to minutes.

Pre-formed mediators released from granules include histamine, heparin, and tryptase. Newly synthesised mediators generated via arachidonic acid metabolism include prostaglandin D2, leukotriene C4/D4/E4 (the slow-reacting substances of anaphylaxis), and platelet-activating factor. Collectively, these produce widespread vasodilation, increased vascular permeability, bronchospasm, increased mucus secretion, and — in systemic anaphylaxis — cardiovascular collapse. Serum tryptase, measurable in the 1–6 hour window post-reaction, serves as both a diagnostic biomarker and a medicolegal record; NICE guidelines on anaphylaxis recommend its measurement to confirm the diagnosis retrospectively.

Type II — Cytotoxic (Antibody-Dependent)

In Type II hypersensitivity, IgG or IgM antibodies bind directly to antigens expressed on cell surfaces or the extracellular matrix. This can occur in three ways: activation of the classical complement pathway leading to the membrane attack complex (MAC) and direct cell lysis; opsonisation with phagocytosis by Fc-receptor-bearing macrophages and neutrophils; or antibody-dependent cell-mediated cytotoxicity (ADCC), in which natural killer cells recognise IgG-coated targets and deliver a lethal hit.

Clinically relevant ED examples include acute haemolytic transfusion reactions (ABO incompatibility), immune thrombocytopenic purpura (ITP), Goodpasture syndrome (anti-GBM antibodies causing pulmonary-renal syndrome), and drug-induced haemolytic anaemia from agents such as methyldopa. Onset is typically over hours, distinguishing it from the immediate reaction of Type I.

Type III — Immune Complex-Mediated

Type III reactions arise when soluble antigen-antibody (IgG or IgM) complexes form in relative antigen excess, preventing efficient clearance by the mononuclear phagocyte system. These complexes deposit in the walls of small blood vessels, the glomerular basement membrane, and synovial membranes. Deposited complexes activate complement (generating C3a and C5a anaphylatoxins, and C5a as a potent neutrophil chemoattractant), recruit neutrophils, and trigger local lysosomal enzyme release, culminating in vasculitis, nephritis, and arthritis.

Onset ranges from hours (the local Arthus reaction following subcutaneous antigen injection) to 6–21 days (serum sickness, classically described after heterologous antiserum administration but now more commonly seen with certain biological therapies). Classic exam examples include post-streptococcal glomerulonephritis, SLE-associated vasculitis, and farmer’s lung (extrinsic allergic alveolitis). The key conceptual distinction from Type II is that the antigen is soluble in Type III rather than cell-surface-bound.

Type IV — Delayed-Type Hypersensitivity (T-Cell-Mediated)

Type IV is the only antibody-independent mechanism in the Gell and Coombs classification. On initial exposure, antigen is processed by dendritic cells and presented to naive CD4+ T cells, driving differentiation into Th1 effector cells and the generation of memory T cells. On re-exposure 48–72 hours later, sensitised CD4+ Th1 cells release interferon-gamma (IFN-gamma) and interleukin-2, activating macrophages and generating a granulomatous inflammatory response. CD8+ cytotoxic T cells contribute directly to tissue destruction in some variants.

The 48–72 hour time course is an absolute revision anchor. Prototypical examples include the tuberculin Mantoux reaction (a controlled diagnostic application of Type IV), nickel or latex contact dermatitis, solid organ graft rejection, and — critically for the ED — drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN), which carry significant mortality and demand early specialist input. The BMJ has published extensively on the immunopathogenesis of severe cutaneous adverse reactions as T-cell-mediated cytotoxic processes.

ED Assessment and Management Framework

Whilst comprehensive management of every hypersensitivity subtype is beyond the scope of a single article, a structured ED approach centres on accurate type identification, severity stratification, and mechanistically rational treatment.

For Type I anaphylaxis, immediate recognition of the triad of rapid onset, life-threatening airway/breathing/circulation compromise, and skin or mucosal changes triggers the Resuscitation Council UK anaphylaxis algorithm: intramuscular adrenaline 0.5 mg (1:1000) to the anterolateral thigh, high-flow oxygen, IV fluid resuscitation, and positioning. Antihistamines and corticosteroids are secondary measures — they do not reverse cardiovascular collapse and must never delay adrenaline. A minimum 6-hour observation period is mandated for monophasic reactions; biphasic reactions (occurring in up to 20% of cases) justify extended observation or admission. Serum tryptase should be drawn at 1–2 hours and at 24 hours post-reaction.

For Type II reactions such as acute haemolytic transfusion reactions, immediate cessation of the transfusion, aggressive fluid resuscitation to maintain renal perfusion, and senior haematology input are essential. For Type III serum sickness, NSAIDs address mild arthralgia and fever; systemic corticosteroids are reserved for severe or protracted cases. For Type IV contact dermatitis, potent topical corticosteroids and allergen identification and avoidance are the cornerstones — antihistamines have no meaningful role in pure T-cell-mediated reactions, a distinction the exam specifically probes.

How the MRCEM Primary Exam Tests Hypersensitivity

The MRCEM Primary exam tests this topic at the level of mechanism, classification, and clinical correlation rather than rote memorisation of drug doses. Candidates preparing MRCEM Primary MCQs and practice questions will encounter several recurring question architectures:

• Mechanism identification from a clinical vignette: A patient develops a widespread pruritic rash 72 hours after starting a new drug — which type of hypersensitivity? (Answer: Type IV.) A patient receiving a blood transfusion develops haemoglobinuria 30 minutes in — which type? (Answer: Type II.)
• Mediator identification: Which immunoglobulin class mediates the sensitisation phase of anaphylaxis? (Answer: IgE.) Which complement components act as anaphylatoxins in Type III disease? (Answer: C3a and C5a.)
• Treatment rationale: Why does adrenaline, rather than chlorphenamine, constitute first-line treatment for anaphylaxis? Questions on why antihistamines are inappropriate in Type IV dermatitis recur in MRCEM SBA revision material.
• Distinguishing Type II from Type III: A common distractor — both involve IgG and complement activation. The distinguishing feature is cell-surface-bound antigen (Type II) versus soluble circulating immune complexes (Type III).

The RCEM curriculum maps immunopathology under the basic sciences domain, and the MRCEM Primary syllabus explicitly lists immune-mediated disease mechanisms. Candidates who invest time in this area reliably gain marks across multiple question stems.

Revision Pearls: 6 High-Yield Facts

1. ACID mnemonic: Anaphylactic (I), Cytotoxic (II), Immune complex (III), Delayed (IV). Commit this to memory — it anchors the entire classification.
2. Type IV is the odd one out: It is the only type that is antibody-independent and T-cell-mediated. The 48–72 hour onset is its clinical signature.
3. Tryptase confirms Type I anaphylaxis: Serum tryptase peaks at 60–90 minutes post-reaction and returns to baseline by 6–24 hours. A raised baseline tryptase suggests underlying mastocytosis and has implications for long-term allergy management.
4. Leukotriene antagonists (e.g. montelukast) target Type I mediators: Leukotrienes C4/D4/E4 mediate sustained bronchospasm in allergic asthma — a mechanistic bridge between the pathology question and the pharmacology question in the same exam paper.
5. Antigen excess favours Type III complex formation: In relative antibody excess, complexes are large and cleared efficiently. In antigen excess, complexes are small, soluble, and evade phagocytosis — leading to deposition and tissue injury. This principle underlies why serum sickness occurs during the resolution phase of an infection as antibody levels rise.
6. Type II encompasses stimulatory and blocking antibodies (Type IIb): Some classifications recognise a subgroup where antibodies target receptors rather than destroy cells — e.g. Graves disease (stimulatory TSH-receptor antibody) and myasthenia gravis (blocking acetylcholine receptor antibody). These may appear as MRCEM Primary SBA exam distractors.

Common Pitfalls — Where Candidates Lose Marks

• Confusing Type II and Type III: Both involve IgG/IgM and complement. The distinction — cell-surface antigen versus soluble immune complex — is the crux of numerous MRCEM SBA questions. Do not conflate them.
• Assuming antihistamines treat all hypersensitivity: Antihistamines address histamine-mediated symptoms in Type I reactions only. They have no role in Type IV reactions and are an adjunct, not a primary intervention, in anaphylaxis.
• Overlooking the biphasic anaphylaxis risk: Candidates underestimate observation requirements. The Resuscitation Council UK guidance and NICE clinical knowledge summaries on anaphylaxis both address this; failing to observe patients adequately is a patient safety issue and an exam pitfall.
• Misattributing serum sickness onset: Serum sickness (Type III) occurs 6–21 days after antigen exposure — not immediately. Candidates who see fever, arthralgia, and rash and reflexively answer Type I will lose marks.
• Forgetting that Stevens-Johnson syndrome is Type IV: Drug-induced SJS/TEN is driven by CD8+ cytotoxic T cells, not IgE. It is emphatically not Type I despite being drug-induced and presenting in the ED with apparent widespread skin involvement.
• Neglecting the pharmacological links: The MRCEM Primary pathology revision questions on hypersensitivity frequently integrate with MRCEM Primary pharmacology revision. Understanding why beta-blockers worsen anaphylaxis (attenuating adrenaline’s beta-2-mediated bronchodilation) and why ACE inhibitors precipitate angioedema (bradykinin accumulation, not IgE-mediated) requires cross-domain integration.

How EM Learning Centre Supports Your MRCEM Primary Revision

MRCEM Primary pathology revision demands more than passive reading — it requires active recall, question-based learning, and spaced repetition across the full breadth of the basic sciences syllabus. The MRCEM Primary revision course at EM Learning Centre provides structured, consultant-authored content mapped directly to the RCEM curriculum, covering immunopathology alongside anatomy, physiology, pharmacology, and microbiology in an integrated, examination-focused format.

Our question bank includes high-fidelity MRCEM SBA practice questions written at examination standard, with detailed explanations that do not merely state the correct answer but explain why the distractors are wrong — the reasoning that converts borderline candidates into confident passers. Whether you are building your foundational knowledge or stress-testing your revision in the weeks before the exam, the EM Learning Centre provides the structured, evidence-grounded platform that UK EM trainees need to perform at their best on the MRCEM Primary exam.

References

1. Resuscitation Council UK. Emergency Treatment of Anaphylaxis: Guidelines for Healthcare Providers. 2021. Resuscitation Council UK
2. National Institute for Health and Care Excellence. Anaphylaxis: Assessment and Referral After Emergency Treatment. CG134. NICE, 2011 (updated 2020). NICE
3. National Institute for Health and Care Excellence. Anaphylaxis — Clinical Knowledge Summary. NICE Clinical Knowledge Summaries
4. The BMJ. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. BMJ Publishing Group. The BMJ
5. Royal College of Emergency Medicine. MRCEM Primary Curriculum and Syllabus. RCEM, 2023. Royal College of Emergency Medicine